Schedule 13G ownership disclosure
INTERCEPT PHARMACEUTICALS IN
Security class unavailable · CUSIP: 45845P108
Event date: 2019-07-25
Legacy cover-page extraction is best effort and may not include every reporting person.
- Filing-level shares
- 6,095,578
- Percent of class
- 20.5000%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000897204-19-000026
- Form type
- SC 13G
- Filer
- Genextra S.p.A.
- CIK
- CIK 1559515
- Filed
- Jul 31, 2019
- Reporting period
- Jul 25, 2019
- Description
- Schedule 13G beneficial ownership